ONCO

Onconetix, Inc. (ONCO) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Onconetix, Inc. is a commercial-stage biotechnology company focused on oncology, primarily through its subsidiary Proteomedix AG and its diagnostic product, Proclarix. The Company abandoned its previous ENTADFI product line in 2024. As of the filing date, the Company is a non-accelerated filer, smaller reporting company, and emerging growth company. The Company has executed a 1-for-5 reverse stock split effective March 25, 2026.

Key Financial Metrics

Note: Working Capital calculated as Total Current Assets ($4,329,354) minus Total Current Liabilities ($3,065,574).

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased by approximately 79% to $21,457, driven by lower product sales from Proteomedix due to reduced customer demand and timing of orders.
• Goodwill Impairment: The Company recorded a goodwill impairment charge of $8.1 million, compared to $10.9 million in Q1 2025, triggered by declines in stock price and market capitalization.
• Derivative Liability Gains: Net loss was significantly reduced by non-cash gains totaling approximately $6.0 million from changes in the fair value of Series D and Series E derivative liabilities ($3.96M and $2.07M, respectively).
• Liability Reduction: Total liabilities decreased by over $6 million, primarily due to the revaluation of derivative liabilities and the settlement of certain obligations.
• Stock Structure: A 1-for-5 reverse stock split was effected in March 2026, adjusting share counts and per-share data retrospectively.

Guidance, Outlook, and Risks

• Going Concern: The Company has raised substantial doubt about its ability to continue as a going concern for one year from the issuance date. Cash on hand ($3.7M) is insufficient to fund operations through December 2026 without additional financing.
• Realbotix Transaction: On February 11, 2026, the Company entered into a Share Exchange Agreement to acquire Realbotix, LLC. Closing is contingent on raising at least $12.5 million in "Net Cash" and obtaining stockholder approval. Failure to close could result in termination fees up to $2.0 million plus expenses.
• Capital Needs: Management plans to fund operations through the commercialization of Proclarix, an Equity Line of Credit (ELOC), and additional equity/debt financings. There are no committed sources of financing beyond the ELOC, which management deems insufficient alone.
• Internal Controls: The Company identified material weaknesses in internal controls over financial reporting, including inadequate segregation of duties, ineffective risk assessment, and insufficient IT general controls.
• Board Changes: Subsequent to the period end, two directors resigned, and Sammy Dorf was appointed Chairman. Josh Epstein was elected to the Board.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $3.7M cash balance against the stated burn rate and the timeline for the Realbotix transaction closing.
• Realbotix Conditions: Confirm the status of the $12.5M Net Cash condition and the progress of the required equity line of credit commitment.
• Derivative Valuation: Review the Level 3 inputs and assumptions (e.g., 150% volatility, 40% probability of closing) used to value the derivative liabilities, which significantly impacted the net loss.
• Goodwill Impairment: Assess the methodology used for the $8.1M impairment and the remaining carrying value of goodwill ($10.2M) relative to the Company's market cap.
• Internal Control Remediation: Evaluate the specific steps being taken to remediate the identified material weaknesses in financial reporting and IT controls.